Euthymics Bioscience Increases Series A Financing to Advance Second Program

EB-1020, a Triple Reuptake Inhibitor Optimized for Adult ADHD, Advances into Pre-IND Development

 

Press Release-Series A Expansion_030811_FINALfinal2